Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

NHS funding

NHS England to trial pre-exposure prophylaxis for HIV prevention before full roll-out

Three-year clinical trial will cost NHS England £10m and will focus on how long participants stay on PrEP and the impact the product has on HIV incidence. 

Man holding Truvada PrEP pill

Source: Directphoto Collection / Alamy Stock Photo

The £10m, three-year trial will test the use of pre-exposure prophylaxis (PrEP) in at least 10,000 patients to examine its effect on HIV incidence ahead of a national roll-out

NHS England has announced it will fund a large-scale clinical trial on the use of pre-exposure prophylaxis (PrEP) for the prevention of HIV ahead of a national roll-out.

The announcement follows the Court of Appeal ruling in November 2016 that said NHS England does have the power, although not the obligation, to fund the provision of antiretroviral drugs for the prevention of HIV.

The three-year trial, which is expected to start early in the 2017–2018 financial year and include at least 10,000 people, will focus on how long participants at high risk of HIV infection stay on PrEP and what impact the preventative product has on the incidence of HIV and sexually transmitted infections.

The trial is expected to cost up to £10m and will be fully funded by NHS England, which will work with local authorities, the Local Government Association (LGA) and Public Health England (PHE) to implement the findings as part of a wider national roll-out.

Although there is strong evidence supporting the clinical effectiveness of PrEP, PHE says there are questions to consider before use of the product is implemented on a substantial scale in England. These include what proportion of genitourinary medicine (GUM) clinic attendees will be assessed as eligible for PrEP; how to identify and maintain other eligible PrEP users; what proportion of eligible people will accept PrEP; and whether participants choose daily or intermittent dosing.

Ian Williams, chair of NHS England’s clinical reference group for HIV, says: “This announcement demonstrates NHS England’s commitment to fund PrEP and provides the chance to best prepare England for optimal roll-out following this large-scale clinical trial.”

Izzi Seccombe, chair of the LGA’s community well-being board, says: “We are pleased that NHS England has acted quickly and chosen to fund the commissioning of this trial and roll-out of PrEP.”

Gilead Sciences, the manufacturer of the branded PrEP drug Truvada, as well as generic firms, are now invited to make proposals to participate in the trial.

Jonathan Fielden, director of specialised commissioning and deputy national medical director at NHS England, says the trial “has, in part, been made possible by the willingness of many pharmaceutical and device companies to come forward with lower and more responsible prices”.

However, he adds that NHS England has had to make “some tough decisions”, which means some specialised treatments for other conditions could not be funded this year. “We will ensure those treatments have the opportunity to be considered as part of the next annual prioritisation round in spring 2017.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20202044

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Essentials of Economic Evaluation in Healthcare

    Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • MCQs in Clinical Pharmacy

    MCQs in Clinical Pharmacy

    Four practice tests, each with 80 practice-oriented MCQs. Assess your knowledge of clinical issues, evaluative and analytical skills.

    £25.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Man holding Truvada PrEP pill

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.